With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.59702-07-7,1-Methylpiperazin-2-one,as a common compound, the synthetic route is as follows.
Step 3: A mixture of 50 mg (0.10 mmol) intermediate VI.4 step 2, 14 mg (0.12 mmol) 1 – Methylpiperazin-2-one, 18 mg (0.13 mmol) K2CO3, 3 mg (0.02 mmol) Nal and acetonitrile is heated to 80°C in a sealed tube for 7 h. Additional 14 mg (0.12 mmol) 1 – Methylpiperazin-2-one and 18 mg (0.13 mmol) K2CO3 are added and the mixture is heated to 100°C in a sealed tube for 13 h. After cooling to RT the solvent is evaporated and DCM and water are added. The organic phase is separated, dried, filtered and evaporated yielding 4-[2-[7-bromo-4-[4-fluoro-2-[(1 R)-2,2,2-trifluoro-1 -methyl- ethoxy]anilino]-5-methyl-quinazolin-6-yl]oxyethyl]-1 -methyl-piperazin-2-one. (0642) Yield: 50 mg (Yield 87percent), ESI-MS: m/z = 600 Mu+EtaGamma, R,(HPLC): 1 .06 min (HPLC-M), 59702-07-7
The synthetic route of 59702-07-7 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; BLUM, Andreas; WO2015/169677; (2015); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics